Hi, great work once again. wouldn’t you include Covid, it would still add to the valuation. Maybe not by a huge multiple. we might be required to do another trial for non-covidArds. It might not be a two for one deal. Could be still prescribed off label you would think, the price tag without insurance may be a problem. Just my thoughts.
the Edison report might not have been the one I was thinking about, unless they’ve changed their logo. It was a running writing type logo. My papers are all boxed up in storage Atm.
I would agree 50% is a bit high for gvhd imo
COVID-19 ARDS and ARDS Share Price Scenarios, page-243
-
- There are more pages in this discussion • 276 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |